- Trials with a EudraCT protocol (1,550)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,550 result(s) found for: diabetes type=2.
Displaying page 62 of 78.
EudraCT Number: 2006-000694-30 | Sponsor Protocol Number: 01-05-TL-322OPI-001 | Start Date*: 2006-09-21 |
Sponsor Name:Takeda Europe Research & Development Centre Ltd., | ||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS) in Subjects with Type ... | ||
Medical condition: Type II Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Completed) LV (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000703-18 | Sponsor Protocol Number: S1713012 | Start Date*: 2004-10-27 |
Sponsor Name:SOLVAY PHARMACEUTICALS GMBH | ||
Full Title: A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure le... | ||
Medical condition: Essential hypertension with associated Diabetes Mellitus type 2. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001252-36 | Sponsor Protocol Number: DM/PR/7401/009/03 | Start Date*: 2004-11-04 | |||||||||||
Sponsor Name:CHIESI | |||||||||||||
Full Title: DOUBLE BLIND, RANDOMISED, PARALLEL GROUP, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF CHF 1521 (FIXED COMBINATION OF MANIDIPINE AND DELAPRIL) VS LOSARTAN 50 MG AND HYDROCHLOROTHI... | |||||||||||||
Medical condition: mild to moderate hypertension in type 2 diabetic patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000847-89 | Sponsor Protocol Number: BELS1001 | Start Date*: 2007-06-27 | |||||||||||
Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust | |||||||||||||
Full Title: Full Title of Study: Diabetic macular oedema: a prospective randomised trial of management with intravitreal bevacizumab (Avastin) versus conventional laser therapy | |||||||||||||
Medical condition: Diabetic macular oedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003279-38 | Sponsor Protocol Number: TZP-101-CL-G004 | Start Date*: 2007-08-17 |
Sponsor Name:Tranzyme Inc. | ||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute I.V. Infusion to Subjects with Severe G... | ||
Medical condition: TZP-101 will be developed as a first-in class therapy for the treatment of gastric dysmotility. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001219-31 | Sponsor Protocol Number: CLAF237A2387 | Start Date*: 2006-09-20 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformin | ||
Medical condition: Type II Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001055-50 | Sponsor Protocol Number: EP-001 | Start Date*: 2016-08-08 |
Sponsor Name:Empros Pharma AB | ||
Full Title: A, single center, controlled, multiple dose, randomized study during two weeks, investigating the effect of the test formulation on efficacy, safety and markers for appetite regulation, glucose and... | ||
Medical condition: Obesity and diabetes, type 2. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003614-27 | Sponsor Protocol Number: GIA-DAP-16-005 | Start Date*: 2017-08-16 | |||||||||||
Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI | |||||||||||||
Full Title: Study on the effect of dapagliflozin on myocardial insulin sensitivity and perfusion (DapaHeart) | |||||||||||||
Medical condition: TYPE 2 DIABETES | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002073-56 | Sponsor Protocol Number: Aramchol-018 | Start Date*: 2020-01-06 | |||||||||||
Sponsor Name:Galmed Research and Development, Ltd. | |||||||||||||
Full Title: A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMO... | |||||||||||||
Medical condition: Nonalcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) BE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000165-12 | Sponsor Protocol Number: RLY5016-205 | Start Date*: 2011-05-27 | |||||||||||||||||||||
Sponsor Name:Relypsa, Inc. | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of RLY5016 in the Treatment of Hyperkalemia in Patients with Hypertension and Diabetic Nephropathy Rece... | |||||||||||||||||||||||
Medical condition: Hyperkalemia in Patients with Hypertension and Diabetic Nephropathy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) DE (Prematurely Ended) AT (Prematurely Ended) SI (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001062-40 | Sponsor Protocol Number: CSPP100A2307 | Start Date*: 2004-12-21 |
Sponsor Name:Novartis Pharma CH | ||
Full Title: An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in p... | ||
Medical condition: patients with both hypertension and diabetes mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Completed) IT (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002791-33 | Sponsor Protocol Number: 2007-17 | Start Date*: 2008-04-16 |
Sponsor Name:Assistance Publique Hopitaux de marseille | ||
Full Title: Effet aigu d’une insulinothérapie intensive sur le métabolisme des lipoparticules riches en triglycérides (LRT) intestinales chez le patient diabétique de type 2 | ||
Medical condition: DIABETIQUE DE TYPE II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000979-16 | Sponsor Protocol Number: ESR-17-12784 | Start Date*: 2019-08-21 |
Sponsor Name:Dr. Guillem Cuatrecasas - CPEN S.L. | ||
Full Title: Dapagliflozin effect in the reduction of different abdominal fat layers in type 2 diabetic patients. | ||
Medical condition: Abdominal fat layers in type 2 diabetic patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001547-12 | Sponsor Protocol Number: DC2017RACELINES01 | Start Date*: 2017-12-21 |
Sponsor Name:VU University Medical Center | ||
Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ... | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019795-74 | Sponsor Protocol Number: CRFB002D2304 | Start Date*: 2010-10-18 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs. 0.5 mg ranibi... | |||||||||||||
Medical condition: Diabetic Macular Edema (DME) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) FR (Completed) ES (Completed) HU (Completed) IT (Completed) IE (Completed) GR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003818-26 | Sponsor Protocol Number: K-877-302 | Start Date*: 2017-03-16 | |||||||||||
Sponsor Name:Kowa Research Institute, Inc. | |||||||||||||
Full Title: Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes (PROMINENT) | |||||||||||||
Medical condition: Reduction of cardiovascular events in patients with Type II Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) NL (Prematurely Ended) BG (Prematurely Ended) DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005793-63 | Sponsor Protocol Number: CLIK066A2202 | Start Date*: 2013-10-30 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with seven doses of LIK066 compared with placebo... | ||
Medical condition: Type II Diabetes mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-000723-14 | Sponsor Protocol Number: 20120119 | Start Date*: 2014-07-11 |
Sponsor Name:Amgen Inc. | ||
Full Title: A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia... | ||
Medical condition: Hyperlipidemia or mixed dyslipidemia in Diabetic Subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001587-30 | Sponsor Protocol Number: 012657 | Start Date*: 2019-07-26 | ||||||||||||||||
Sponsor Name:Queen Mary University London | ||||||||||||||||||
Full Title: AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce | ||||||||||||||||||
Medical condition: renal transplant AND type 2 diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001190-25 | Sponsor Protocol Number: A6291015 | Start Date*: 2004-12-17 |
Sponsor Name:Pfizer Ltd | ||
Full Title: A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensi... | ||
Medical condition: Diabetic nephropathy DN (Diabetes mellitus (DM) type I and type II with renal manifestations). MedDRA classification code : 10061835, 10045236 and 10045250 (Version 7.0, Level LLT) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed) DK (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
